BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 16872514)

  • 21. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
    Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
    J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
    Sihvonen S; Korpela M; Mustila A; Mustonen J
    J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis.
    Berglin E; Padyukov L; Sundin U; Hallmans G; Stenlund H; Van Venrooij WJ; Klareskog L; Dahlqvist SR
    Arthritis Res Ther; 2004; 6(4):R303-8. PubMed ID: 15225365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations.
    Korkmaz C; Us T; Kaşifoğlu T; Akgün Y
    Clin Biochem; 2006 Oct; 39(10):961-5. PubMed ID: 16979149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels.
    Bos WH; Ursum J; de Vries N; Bartelds GM; Wolbink GJ; Nurmohamed MT; van der Horst-Bruinsma IE; van de Stadt RJ; Crusius JB; Tak PP; Dijkmans BA; van Schaardenburg D
    Ann Rheum Dis; 2008 Sep; 67(9):1347-50. PubMed ID: 18388157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
    Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
    Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study.
    Pedersen M; Jacobsen S; Klarlund M; Frisch M
    J Rheumatol; 2006 Jun; 33(6):1069-74. PubMed ID: 16622905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
    Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
    Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis.
    van Oosterhout M; Bajema I; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2008 Jan; 58(1):53-60. PubMed ID: 18163491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives.
    El-Gabalawy HS; Robinson DB; Hart D; Elias B; Markland J; Peschken CA; Smolik I; Montes-Aldana G; Schroeder M; Fritzler MJ; Cheang M; Oen K
    J Rheumatol; 2009 Jun; 36(6):1130-5. PubMed ID: 19411392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redefining the HLA and RA association: to be or not to be anti-CCP positive.
    de Vries RR; Huizinga TW; Toes RE
    J Autoimmun; 2005; 25 Suppl():21-5. PubMed ID: 16257178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis.
    Poór G; Nagy ZB; Schmidt Z; Brózik M; Merétey K; Gergely P
    Ann N Y Acad Sci; 2007 Sep; 1110():23-32. PubMed ID: 17911417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study.
    Amezcua-Guerra LM; Springall R; Marquez-Velasco R; Gómez-García L; Vargas A; Bojalil R
    Arthritis Res Ther; 2006; 8(5):R144. PubMed ID: 16934155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis.
    Inui N; Enomoto N; Suda T; Kageyama Y; Watanabe H; Chida K
    Clin Biochem; 2008 Sep; 41(13):1074-7. PubMed ID: 18638466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
    Johansson M; Arlestig L; Hallmans G; Rantapää-Dahlqvist S
    Arthritis Res Ther; 2006; 8(1):R19. PubMed ID: 16507117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
    Galati S; Beauvillain C; Renier G; Jeannin P; Masson C; Chevailler A
    Ann Biol Clin (Paris); 2008; 66(2):157-64. PubMed ID: 18390426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis.
    Ferucci ED; Majka DS; Parrish LA; Moroldo MB; Ryan M; Passo M; Thompson SD; Deane KD; Rewers M; Arend WP; Glass DN; Norris JM; Holers VM
    Arthritis Rheum; 2005 Jan; 52(1):239-46. PubMed ID: 15641089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.